An experimental oral drug called remibrutinib outperformed the approved therapy Aubagio (teriflunomide) in reducing disease flare rates in two large, late-stage clinical trials involving people with relapsing forms of multiple sclerosis (MS). That’s according to top-line data — the studies’ first results — announced by remibrutinib’s developer…

Anti-inflammatory diets may help to ease fatigue and improve overall physical health in people with multiple sclerosis (MS), according to a new analysis of data from 10 clinical trials. Findings also indicated that anti-inflammatory diets do not substantially alter body composition, disability status, or mental health in MS patients.

Immunic says it’s on track to announce early data by year’s end from twin late-stage trials testing vidofludimus calcium (IMU-838) — an oral therapy believed to have both anti-inflammatory and neuroprotective properties — in people with relapsing forms of multiple sclerosis (MS). The top-line results from the…

Treatment with neural stem cells — cells that have the ability to mature into supportive cells of the brain and spinal cord — showed early signs of neuroprotection in people with progressive forms of multiple sclerosis (MS), according to long-term follow-up data from a small early clinical trial. The…

Recent updates to the McDonald criteria — the internationally recognized guidelines used to diagnose multiple sclerosis (MS) — may support earlier and more accurate diagnoses. But the changes are also expected to require researchers to rethink how clinical trials testing new MS therapies are run, and better biomarkers…

AB Science is stopping a late-stage clinical trial testing its oral drug masitinib as a treatment for progressive forms of multiple sclerosis (MS), saying this study and the therapy’s clinical development for MS are no longer a priority for the company. Instead, the developer will advance masitinib for…

A research team at the University of California, Los Angeles (UCLA) has received a $7.49 million grant to advance a novel cell-based therapy for multiple sclerosis (MS) toward its first clinical trial. The state funding, awarded by the California Institute for Regenerative Medicine (CIRM), was earmarked for a team…

Increasing the dose of the infusion therapy Ocrevus (ocrelizumab) does not provide additional benefit compared with the approved regimen in slowing disability progression for people with relapsing forms of multiple sclerosis (MS) or primary progressive MS. That’s according to final data from two global Phase 3b clinical…

The U.S. Food and Drug Administration (FDA) has given Pheno Therapeutics the green light to begin clinical testing of PTD802, the company’s oral lead treatment candidate for boosting myelin repair in people with multiple sclerosis (MS) and other neurological diseases. The experimental remyelination therapy aims to potentially…